Posted by Michael Wonder on 29 Aug 2024
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
27 August 2024 - TruSight Oncology Comprehensive is the first US FDA approved, distributable comprehensive genomic profiling Iin vitro diagnostic kit with pan-cancer companion diagnostic claims.
Illumina today announced FDA approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications.
